J Remon1, E Nadal2, M Dómine3, J Ruffinelli2, Y García4, J C Pardo5, R López6, A Cilleruelo7, R García-Campelo8, P Martín9, O Juan10, J L González-Larriba11, M Provencio12, E Olmedo13, S Ponce14, D Cumplido15, C Barenys16, M Majem17, B Massutti18, D Rodriguez-Abreu19, R Porta20, M A Sala21, M Martinez-Kareaga22, P Lianes1, N Reguart23. 1. Hospital de Mataró, Medical Oncology Department, Mataró, Barcelona, Spain. 2. Institut Català d'Oncologia, ICO-Bellvitge, Medical Oncology Department, Hospitalet del Llobregat, Barcelona, Spain. 3. Hospital Universitario Fundación Jiménez Diaz, Medical Oncology Department, Madrid, Spain. 4. Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí I3PT, Universitat Autònoma de Barcelona, Medical Oncology Department, Sabadell, Barcelona, Spain. 5. Institut Català d'Oncologia, Medical Oncology Department, Applied Research Group in Oncology (B·ARGO), Badalona, Spain. 6. Hospital Clínico Universitario de Valladolid, Medical Oncology Department, Valladolid, Spain. 7. Hospital Clínico Universitario de Valladolid, Thoracic Surgery Department, Valladolid, Spain. 8. Hospital Materno Infantil Teresa Herrera, Medical Oncology Department, A Coruña, Spain. 9. Hospital Clínico Universitario de Valencia, Medical Oncology Department, Valencia, Spain. 10. Hospital Universitari i Politècnic La Fe, Medical Oncology Department, Valencia, Spain. 11. Hospital Clínico San Carlos, Medical Oncology Department, Madrid, Spain. 12. Hospital Universitario Puerta de Hierro, Medical Oncology Department, Majadahonda, Madrid, Spain. 13. Hospital Ramón y Cajal, Medical Oncology Department, Madrid, Spain. 14. Hospital 12 de Octubre, Medical Oncology Department, Madrid, Spain. 15. Hospital de Torrevieja, Medical Oncology Department, Torrevieja, Alicante, Spain. 16. Institut Català d'Oncologia, ICO-Bellvitge, Hospital Universitari Germans Trias I Pujol, Thoracic Surgery Department, Badalona, Barcelona, Spain. 17. Hospital de la Santa Creu I Sant Pau, Medical Oncology Department, Barcelona, Spain. 18. Hospital Universitario de Alicante, Medical Oncology Department, Alicante, Spain. 19. Hospital Universitario Insular de Gran Canaria, Medical Oncology Department, Las Palmas de Gran Canaria, Spain. 20. Institut Català d'Oncologia, ICO-Girona, Hospital Josep Trueta, Medical Oncology Department, Girona, Spain. 21. Hospital de Basurto, Medical Oncology Department, Vizcaya, Spain. 22. Hospital Universitario de Araba (Sede Txagorritxu), Medical Oncology Department, Vizcaya, Spain. 23. Hospital Clínic i Provincial de Barcelona, Medical Oncology Department, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Translational Genomics and Targeted Therapeutics in Solid Tumors Department, Barcelona, Spain. Electronic address: nreguart@clinic.cat.
Abstract
BACKGROUND: Malignant mesothelioma is a rare but aggressive tumor arising from the pleura, typically associated with exposure to asbestos. The purpose of this investigation was to describe mesothelioma patient characteristics, treatment patterns, and outcomes in Spain. MATERIAL AND METHODS: Patients diagnosed with malignant mesothelioma of the pleura were recorded in an anonymous online database (BEMME, Epidemiologic Spanish Malignant Mesothelioma Database) from June 2008 through May 2013. Patient and tumor characteristics at time of diagnosis, as well as subsequent treatments (surgery, radiation, and chemotherapy), were collected. Among patients treated with chemotherapy, we explored type of chemotherapy regimen and outcomes by treatments. RESULTS: A total of 560 malignant pleural mesothelioma (MPM) patients were recorded. The median age at diagnosis was 68 years, mainly with epithelioid histology (62 %), and any asbestos exposure was noted in 45 % of patients. Nearly two-thirds of patients (71 %) received chemotherapy, mainly platinum-pemetrexed combination, as part of their treatment. Surgery and radiotherapy were given in 36 % and 17 % of patients, respectively. The median overall survival (OS) in the whole cohort was 13.0 months (95 % confidence interval (CI), 11.1-14.8 months) with 1-year OS of 53.2 % (95 % CI, 48.7-57.7 %). In patients receiving first-line chemotherapy (N = 315), the median OS was 13.4 months (95 % CI, 10.8-16.0 months), reaching 20.2 months (95 % CI, 17.2-23.2 months) for those 68 patients receiving maintenance chemotherapy. Results of multivariate analyses showed significant association of ECOG-performance status, histology and treatment response with improved OS in MPM patients treated with palliative chemotherapy. CONCLUSIONS: Despite multimodal therapeutic intervention, survival of patients with mesothelioma in Spain remains poor. Although it did not reach significance in the multivariate analysis, a meaningful additional survival benefit was observed among those patients receiving maintenance chemotherapy.
BACKGROUND:Malignant mesothelioma is a rare but aggressive tumor arising from the pleura, typically associated with exposure to asbestos. The purpose of this investigation was to describe mesotheliomapatient characteristics, treatment patterns, and outcomes in Spain. MATERIAL AND METHODS:Patients diagnosed with malignant mesothelioma of the pleura were recorded in an anonymous online database (BEMME, Epidemiologic Spanish Malignant Mesothelioma Database) from June 2008 through May 2013. Patient and tumor characteristics at time of diagnosis, as well as subsequent treatments (surgery, radiation, and chemotherapy), were collected. Among patients treated with chemotherapy, we explored type of chemotherapy regimen and outcomes by treatments. RESULTS: A total of 560 malignant pleural mesothelioma (MPM) patients were recorded. The median age at diagnosis was 68 years, mainly with epithelioid histology (62 %), and any asbestos exposure was noted in 45 % of patients. Nearly two-thirds of patients (71 %) received chemotherapy, mainly platinum-pemetrexed combination, as part of their treatment. Surgery and radiotherapy were given in 36 % and 17 % of patients, respectively. The median overall survival (OS) in the whole cohort was 13.0 months (95 % confidence interval (CI), 11.1-14.8 months) with 1-year OS of 53.2 % (95 % CI, 48.7-57.7 %). In patients receiving first-line chemotherapy (N = 315), the median OS was 13.4 months (95 % CI, 10.8-16.0 months), reaching 20.2 months (95 % CI, 17.2-23.2 months) for those 68 patients receiving maintenance chemotherapy. Results of multivariate analyses showed significant association of ECOG-performance status, histology and treatment response with improved OS in MPM patients treated with palliative chemotherapy. CONCLUSIONS: Despite multimodal therapeutic intervention, survival of patients with mesothelioma in Spain remains poor. Although it did not reach significance in the multivariate analysis, a meaningful additional survival benefit was observed among those patients receiving maintenance chemotherapy.
Authors: Arnulf Holzknecht; Oliver Illini; Maximilian J Hochmair; Dagmar Krenbek; Ulrike Setinek; Florian Huemer; Erwin Bitterlich; Christoph Kaindl; Vladyslav Getman; Ahmet Akan; Michael Weber; Gunther Leobacher; Arschang Valipour; Michael R Mueller; Stefan B Watzka Journal: Cancers (Basel) Date: 2022-04-30 Impact factor: 6.575